23. 6. 2017

Hotel Holiday Inn, Bratislava

SOLEN, s.r.o.

Slovenská onkologická spoločnosť

10 €

Registračný poplatok zahŕňa: účasť na odbornom programe, kongresové materiály (taška, program, abstrakty) a občerstvenie v hodnote 5€.
Uhradený registračný poplatok je nevratný.

Odborné podujatie je zaradené do kontinuálneho medicínskeho vzdelávania.
Registrovaní účastníci dostanú na záver podujatia potvrdenie o účasti s kreditmi CME.

Odborný program

8.00 – 8.30 Registration

8.30 – 8.35 Welcome

President of Slovak Oncology Society, Tomáš Šálek

I. Malignant Melanoma/Lung Cancer Session

Chairmen: Juraj Beniak, Peter Kasan (8.35 – 9.40)

8.35 – 8.55 1. Malignant Melanoma (Zuzana Pribulová, VOÚ, Košice)

1. Abstract # 9504 Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE- 006 study who completed pembrolizumab (pembro) treatment. (Caroline Robert)
2. Abstract # 9505 Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600 – mutant unresectable or metastatic melanoma (MM). (Georgina Long)
3. Abstract # 9507 Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. (Hussein Tawbi)
4. Abstract # 9508 A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti- PD1 Brain Collaboration (ABC). (Georgina Long)

8.55 – 9.15 2. Lung Cancer (Peter Beržinec, ŠN sv. Svorada, Nitra)

1. Abstract # 8500 Gefitinib (G) versus vinorelbine + cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR - activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). (Yi-Long Wu)
2. Abstract # 8503 Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. (Matthew Hellmann)
3. Abstract # 8505 Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study. (Taofeek Owonikoko)
4. Abstract # LBA8507 Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. (Arnaud Scherpereel)
5. Abstract # 9000 Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024. (Julie Brahmer)
6. Abstract # 9004 Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo). (Jaafar Bennouna)
7. Abstract # LBA9007 Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. (Tony Mok)
8. Abstract # LBA9008 Alectinib versus crizotinib in treatment-naive advanced ALK -positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (Alice Shaw)

9.15 – 9.40 Discussion

II. Gastrointestinal Cancer Session

Chairmen: Tomáš Šálek, Radovan Barilla (9.40 – 10.45)

9.40 – 10.00 3. Gastrointestinal cancer (Colorectal) (Marián Kakalejčík, POKO Poprad)

1. Abstract # 3503 Primary (1°) tumor location is an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). (Alan Venook)
2. Abstract # 3505 Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). (Scott Kopetz)
3. Abstract # 3507 Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. (Ricky Sharma)
4. Abstract # LBA1 Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. (Qian Shi)

10.00 – 10.20 4. Gastrointestinal (Non-Colorectal) Cancer (Patrik Palacka, NOÚ)

1. Abstract # 4001 Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). (Ann-Lii Cheng)
2. Abstract # 4006 Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. (John Primrose)
3. Abstract # 4007 Results of the randomized phase II portion of NRG Oncology/RTOG 0848 evaluating the addition of erlotinib to adjuvant gemcitabine for patients with resected pancreatic head adenocarcinoma. (Howard Safran)
4. Abstract # 4014 Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy- refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. (Yelena Janjigian)

10.20 – 10.45 Discussion

10.45 – 11.05 Coffee-Break

III. Gynecologic/Genitourinary Cancer Session

Chairmen: Igor Andrašina, Jozef Mardiak (11.05 – 12.10)

11.05 – 11.25 5. Gynecologic Cancer (Juraj Beniak, POKO Poprad)

1. Abstract # 5502 Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with highrisk endometrial cancer. (Stephanie De Boer)
2. Abstract # 5505 A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. (Daniela Matei)
3. Abstract # 5506 Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. (Jonathan Ledermann)
4. Abstract # 5507 Effect of health-related quality of life (HRQOL) and patient-centered outcomes on the clinical benefit of prolongation of progression-free survival (PFS) with olaparib maintenance following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial. (Michael Friedlander)

11.25 – 11.45 6. Genitourinary Cancer (Michal Mego, NOÚ, Bratislava)

1. Abstract # 4501 Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (Dean Bajorin)
2. Abstract # 4502 Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin- ineligible advanced urothelial cancer (UC). (Peter O’Donnell)
3. Abstract # 4507 Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). (Robert Motzer)
4. Abstract # 4508 Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. (Bernard Escudier)
5. Abstract # 5002 A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). (Kim Chi)
6. Abstract # LBA5003 Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476). (Nicholas James)
7. Abstract # 5004 A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). (Gerhardt Attard)
8. Abstract #5009 Germline genetic testing results in relation to re-evaluation of current guidelines in prostate cancer. (Piper Nicolosi)
9. Abstract #LBA3 LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Karim Fizazi)

11.45 – 12.10 Discussion

12.10 – 13.10 Lunch

IV. Breast Cancer Session

Chairmen: Mária Wagnerová, Michal Mego (13.10 – 14.15)

13.10 – 13.30 7. Breast Cancer – Metastatic (Igor Andrašina, VOÚ, Košice)

1. Abstract # 1000 MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy (George Sledge)
2. Abstract # 1001 Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2– advanced breast cancer (PALOMA-1; TRIO-18). (Richard Finn)
3. Abstract # 1008 Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. (Sylvia Adams)
4. Abstract # LBA4 OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). (Mark Robson)

13.30 – 13.50 8. Breast Cancer – Local/Regional/Adjuvant (Bibiana Vertáková-Krakovská, OÚSA, Bratislava)

1. Abstract # LBA 500 APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2- positive early breast cancer (EBC). (Gunter Von Minckwitz)
2. Abstract # 504 Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. (Nadia Harbeck)
3. Abstract # 506 Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. (Laura Esserman)
4. Abstract # 508 Mastectomy rates in relation to adoption of a margin guideline. (Monica Morrow)

13.50 – 14.15 Discussion

V. Patient and Survivor Care/Head&Neck Cancer Session

Chairmen: Dagmar Sorkovská, Jozef Chovanec (14.15 – 15.20)

14.15 – 14.35 9. Patient and Survivor Care (Andrea Škripeková, NOÚ, Bratislava)

1. Abstract # 10009 FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US food and Drug Administration. (Harpreet Singh)
2. Abstract # 10000 Long-term results of a phase II randomized controlled trial (RCT) of a psychological intervention (Conquer Fear) to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Jane Beith)
3. Abstract # 10004 SCORAD III: Randomised non-inferiority phase III trial of single dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). (Peter Hoskin)
4. Abstract # 10006 American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease- free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). (Erin Van Blarigan)
5. Abstract # LBA 2 Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. (Ethan Basch)

14.35 – 14.55 10. Head&Neck Cancer (Pavol Dubinský, VOÚ, Košice)

1. Abstract # 6009 Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). (Robert Haddad)
2. Abstract # 6000 Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG- ACRIN Cancer Research Group trial. (Athanassios Argiris)
3. Abstract # 6002 A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT). (Anthony Chan)
4. Abstract # 6007 Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. (Vanita Noronha)

14.55 – 15.20 Discussion

15.20 – 15.30 Closing remarks

President of Slovak Oncology Society, Tomáš Šálek

Pre účastníkov je ubytovanie zabezpečenév mieste konania: Hotel Holiday Inn, Bratislava www.holidayinn.sk.

Ceny ubytovania:

• dvojlôžková izba – 99 €

(cena je uvedená s DPH, zahŕňa ubytovanie, raňajky, miestny poplatok)*

Ubytovanie je možné rezervovať prostredníctvom organizátora podujatia písomnou formou – prihláška na ubytovanie je súčasťou registračného formulára.Rezervácia je záväzná, zmena je možná bez účtovania storno poplatku do 19. 5. 2017. Po tomto termíne sa o možnostiach ubytovania informujte u organizátora.

SOLEN, s.r.o.

Ambrova 5

831 01 Bratislava

Tel. 02/5413 1365

www.solen.sk

kongres@solen.sk

Monika Horáková, 0903 452 654, horakova@solen.sk